Source comparison
MOTS-c Dosage Protocols: Research vs Community Practice
Research-Supported Standard 5–10mg subcutaneous 2–3× weekly 10–30mg USC metabolic studies, observational human data Strongest evidence for sustained AMPK activation without receptor desensitization. Best starting point for most users. High-Dose Muscle-Sparing
This comparison does not assign a generated winner or score.
- Research-Supported Standard
- 5–10mg subcutaneous
- 2–3× weekly
- 10–30mg
- USC metabolic studies, observational human data
- Strongest evidence for sustained AMPK activation without receptor desensitization. Best starting point for most users.
- High-Dose Muscle-Sparing
- 10–15mg subcutaneous
- 3× weekly
- 30–45mg
- Anecdotal case reports, no controlled trials
- Used during caloric deficits >500 kcal/day. May preserve lean mass but no controlled data confirms additional fat loss vs standard dosing. Risk of receptor downregulation increases above 12mg/dose.
- Daily Micro-Dosing
- 2–5mg subcutaneous
- 5–7× daily
- 10–35mg
- Online peptide forums, no peer review
- Mimics endogenous pulsatile release theory. No evidence this outperforms 2–3× weekly for metabolic outcomes. Higher injection burden with no proven benefit.
- Single Weekly Mega-Dose
- 15–25mg subcutaneous
- 1× weekly
- 15–25mg
- Bodybuilding forums only
- Plasma half-life of 4–6 hours makes this illogical for sustained AMPK signaling. Likely suboptimal for metabolic reprogramming despite anecdotal reports.
- The table above reflects protocols we've encountered in institutional research settings versus what circulates in peptide-focused communities. The research-supported standard. 5–10mg injected 2–3 times weekly. Aligns with MOTS-c's pharmacokinetics and mechanism. Higher-frequency or mega-dose protocols are speculative extrapolations without controlled outcome data.